Moomoo AI 已提取核心信息
Novo Integrated Sciences, Inc. (Novo), a Nevada-based healthcare company, has entered into a securities purchase agreement with RC Consulting Group LLC, issuing a $70 million unsecured 15-year promissory note with a maturity date of April 26, 2038. The note, which was issued at a purchase price of $57 million plus a 1.52% annual yield, is subject to customary events of default, which could lead to an immediate payment obligation of 125% of the outstanding principal plus accrued interest and collection costs. Novo also received a notification from Nasdaq on February 9, 2024, indicating non-compliance with the minimum bid price requirement for continued listing. This non-compliance was considered an event of default under the terms of the securities purchase agreement and the note. However, on February...Show More
Novo Integrated Sciences, Inc. (Novo), a Nevada-based healthcare company, has entered into a securities purchase agreement with RC Consulting Group LLC, issuing a $70 million unsecured 15-year promissory note with a maturity date of April 26, 2038. The note, which was issued at a purchase price of $57 million plus a 1.52% annual yield, is subject to customary events of default, which could lead to an immediate payment obligation of 125% of the outstanding principal plus accrued interest and collection costs. Novo also received a notification from Nasdaq on February 9, 2024, indicating non-compliance with the minimum bid price requirement for continued listing. This non-compliance was considered an event of default under the terms of the securities purchase agreement and the note. However, on February 16, 2024, Novo and the holder entered into a Limited Waiver, exempting the company from the non-compliance determination related to the minimum bid price requirement, but not extending to potential delisting. The waiver does not affect other terms of the agreement, which remain in full force. Novo issued a press release on February 20, 2024, to announce the waiver and emphasize the company's ongoing commitment to providing patient-first health and wellness services through a multidisciplinary approach and technological innovation.
总部位于内华达州的医疗保健公司Novo Integrated Sciences, Inc.（Novo）已与RC Consulting Group LLC签订了证券购买协议，发行了7000万美元的15年期无抵押本票，到期日为2038年4月26日。该票据的发行价格为5700万美元，年收益率为1.52％，受惯例违约事件的影响，这可能导致立即支付未偿本金的125％加上应计利息和收款成本。Novo还于2024年2月9日收到纳斯达克的通知，表示未遵守继续上市的最低出价要求。根据证券购买协议和票据的条款，这种违规行为被视为违约事件。但是，在2024年2月16日，Novo和持有人签订了有限豁免，免除了该公司与最低出价要求相关的违规决定，但不包括潜在的退市。豁免不影响协议的其他条款，这些条款仍然完全有效。Novo于2024年2月20日发布新闻稿，宣布豁免，并强调该公司持续致力于通过多学科方法和技术创新提供患者至上的健康和保健服务。
总部位于内华达州的医疗保健公司Novo Integrated Sciences, Inc.（Novo）已与RC Consulting Group LLC签订了证券购买协议，发行了7000万美元的15年期无抵押本票，到期日为2038年4月26日。该票据的发行价格为5700万美元，年收益率为1.52％，受惯例违约事件的影响，这可能导致立即支付未偿本金的125％加上应计利息和收款成本。Novo还于2024年2月9日收到纳斯达克的通知，表示未遵守继续上市的最低出价要求。根据证券购买协议和票据的条款，这种违规行为被视为违约事件。但是，在2024年2月16日，Novo和持有人签订了有限豁免，免除了该公司与最低出价要求相关的违规决定，但不包括潜在的退市。豁免不影响协议的其他条款，这些条款仍然完全有效。Novo于2024年2月20日发布新闻稿，宣布豁免，并强调该公司持续致力于通过多学科方法和技术创新提供患者至上的健康和保健服务。
有用
没用